Cytosol

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Retrieved on: 
Friday, November 10, 2023

NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.

Key Points: 
  • NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director.
  • Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
  • Most recently, Tony held the position of Chief Executive Officer at Goldfinch Bio and is Chair of the Board of Directors at Outrun Therapeutics.
  • Tony brings extensive and broad expertise to NanoSyrinx, particularly in drug discovery and early clinical development.

Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects

Retrieved on: 
Saturday, November 4, 2023

NEW YORK, Nov. 4, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a Phase 2 stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data demonstrating the molecular mechanism of its lead therapeutic candidate, PT-112, and its ability to induce immunogenic cell death (ICD) in cancer cells. Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism. The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.

Key Points: 
  • Data suggest that PT-112-induced ICD is mediated by endoplasmic reticulum (ER) and mitochondrial stresses, which are specific intra-cellular events that comprise part of the larger ICD mechanism.
  • The presentation was made at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego.
  • PT-112 effects on mitochondria included increases in mitochondrial mass and reactive oxygen species, changes in membrane polarization, and the release of mitochondrial DNA into the cytosol, a potent immunogenic signal.
  • For more information about Promontory Therapeutics and PT-112, visit www.PromontoryTx.com .

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

Serca Pharmaceuticals showcases exciting data on 13-M at Heart Failure 2023

Retrieved on: 
Monday, May 22, 2023

OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023, the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.

Key Points: 
  • OSLO, Norway, May 22, 2023 /PRNewswire/ -- Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and stenting, today announces that it presented data on a novel approach to modulate the Beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility at Heart Failure 2023 , the world leading event on heart failure, in Prague, Czech Republic, 20-23 May 2023.
  • 13-M is a small NCE shown to have these important protein to protein interaction (PPI) characteristics with the capacity to modulate the SERCA2 Ca2+ pump.
  • MI is one of the leading causes of death and disability worldwide, affecting approximately seven million people each year.
  • Without treatment, 30% of MI patients will go on to develop heart failure.

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Retrieved on: 
Monday, May 1, 2023

The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.

Key Points: 
  • The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.
  • Dr. Newman’s second talk, “Pre-Clinical Anti-HBV Activity with a Passively Targeted, Multi-TLR, NOD and STING Agonist,” which features the Company’s infectious disease research on its Decoy platform will be held on May 11th at 2:30PM.
  • Deep diving into the role that the microbiome plays in innate immune regulation to provide a more holistic overview of how the STING and TLR activation are regulated.
  • The event will be held at the Hilton Boston Back Bay in Boston.

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

Retrieved on: 
Thursday, November 10, 2022

LINE-1 reverse transcriptase is an endogenous reverse transcriptase (eRT) encoded by repetitive sequences in the human genome.

Key Points: 
  • LINE-1 reverse transcriptase is an endogenous reverse transcriptase (eRT) encoded by repetitive sequences in the human genome.
  • Since excess activation of these pathways can lead to autoimmune disease, eRT inhibitors have great potential to improve pathological outcomes.
  • Through rational structure-based drug design, ROME identified novel, selective and potent inhibitors of LINE-1 reverse transcriptase.
  • Endogenous reverse transcriptases encoded by repetitive sequences in the human genome are increasingly implicated in many difficult-to-treat diseases, including autoimmune disease.

Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the ISBP 2022 Conference

Retrieved on: 
Thursday, September 15, 2022

WOBURN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (Yield10 or the Company), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (ISBP) 2022 Conference.

Key Points: 
  • WOBURN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (Yield10 or the Company), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (ISBP) 2022 Conference.
  • Yield10 researchers are conducting a program intended to produce sustainable, low-cost PHA bioplastic materials in the seed of the Camelina plant.
  • In a patent application filed in 2019, Yield10 described a new technology solution for deploying the PHB pathway in Camelina.
  • We have successfully demonstrated proof of concept for producing PHA bioplastics in Camelina seed by leveraging advanced tools in synthetic biology, said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.

Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer

Retrieved on: 
Wednesday, June 22, 2022

CAMBRIDGE, Mass., June 22, 2022 /PRNewswire/ -- Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, has appointed Marty J. Duvall as chief executive officer and member of its board of directors.

Key Points: 
  • Duvall brings extensive global oncology drug development and commercialization experiences from executive leadership roles in both large pharmaceutical and biotech companies.
  • Angiex Founder and President Paul Jaminet, said, "Marty joins the Angiex team at the perfect time to help drive our company forward.
  • Iain Dukes, executive chairman of Angiex and venture partner of Orbimed Advisors, said, "Bringing in an executive of Marty's caliber is an important step for Angiex.
  • Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology.

Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the CROPS 2022: Improving Agriculture Through Genomics Conference

Retrieved on: 
Wednesday, June 15, 2022

Yield10 researchers have conducted a research program aimed at producing PHA bioplastics in the seed of the Camelina plant as a sustainable, low-cost method for producing this material.

Key Points: 
  • Yield10 researchers have conducted a research program aimed at producing PHA bioplastics in the seed of the Camelina plant as a sustainable, low-cost method for producing this material.
  • Our team has leveraged advanced tools in synthetic biology to successfully demonstrate proof of concept for producing PHA bioplastics in Camelina seed, said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.
  • This spring we are growing prototype PHA Camelina at the acre-scale and plan to extract the PHA from seed for business development use.
  • Learn more about the CROPS 2022: Improving Agriculture Through Genomics conference on the conference website.

SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation

Retrieved on: 
Tuesday, February 1, 2022

We are excited to publish the comprehensive dataset that has long underpinned our conviction in the SQZ APC platforms potential for patient impact, said Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies.

Key Points: 
  • We are excited to publish the comprehensive dataset that has long underpinned our conviction in the SQZ APC platforms potential for patient impact, said Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies.
  • In this journal article, SQZ scientists and their collaborators describe how they overcome this fundamental biological problem through the delivery of antigens directly into the cytosol of immune cells by microfluidic squeezing.
  • We are exploring an exciting frontier in cell therapy and look forward to assessing its potential for patient impact in our clinical trials.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.